Introduction: EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because cooccurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co-occurring genomic alterations that impact patients' outcomes using a comprehensive gene panel is potentially important.
Introduction
In advanced cases of NSCLC with the presence of EGFR mutations, treatment with EGFR-tyrosine kinase inhibitors (TKIs; e.g., gefitinib, erlotinib, and afatinib) has resulted in higher survival rates as compared with standard chemotherapy. [1] [2] [3] Recently, third-generation EGFR-TKIs (EGFR-TKI 3rd ), such as osimertinib, rociletinib, and olmutinib, have displayed remarkable efficacy against T790M-related resistance mutation-positive NSCLC. [4] [5] [6] Despite initial dramatic responses, genetically driven resistance to targeted therapy eventually emerges, thereby limiting the prolonged effectiveness of TKIs. 7 Furthermore, approximately 20% to 30% of patients do not exhibit objective responses to EGFR-TKIs. [1] [2] [3] Co-occurring genetic alterations might play a role in resistance mechanisms and could potentially explain the marked diversity of individual patient outcomes. 8, 9 Previous studies suggested a potential role of TP53 mutations and alterations in cell-cycle genes in poor therapeutic response. [10] [11] [12] However, specific co-occurring genetic alterations that affect the clinical outcomes of EGFR-TKI 3rd in addition to primary driver mutations remain largely unknown. 12 Statistical analysis of high-throughput sequencing data enables systematic detection of clinically meaningful genetic alterations, making it possible to identify patients potentially sensitive to targeted agents. In this study, we integrated genomic data and curated clinically relevant data to investigate whether co-occurring genetic alterations might serve as prognostic and TKI-responsepredictive biomarkers.
Methods

Patients and Sample Collection
A total of 307 patients with advanced NSCLC harboring EGFR-activating mutations and who received targeted sequencing tests on tumor samples at a single institute (Samsung Medical Center, Seoul, Korea) from January 2014 to May 2017 were screened. Patients harboring TKI-resistant EGFR mutations (exon 20 insertions; S768I and L747P) were excluded. The remaining patients harboring TKI-sensitive common EGFR-activating mutations (in-frame deletions in exon 19, L858R, G719X, L861Q, or L833VþH835L) were included in the study. We classified patients into two cohorts based on EGFR-TKI-treatment status at the time of tissue sampling for next-generation sequencing (NGS) tests. Cohort 1 included patients with NGS results obtained before treatment with first-/second-generation EGFR-TKIs (EGFR-TKI 1st/2nd ). Cohort 2 included patients who acquired the T790M mutation following failure of initial EGFR-TKI treatment and underwent NGS testing on re-biopsied samples obtained before EGFR-TKI 3rd treatment ( Supplementary Fig. 1 ). Patient characteristics were obtained using medical and radiographic records and included age, sex, smoking history, histology, Eastern Cooperative Oncology Group (ECOG) score, treatment duration, and information on death and tumor progression. Data collection was approved by the Samsung Medical Center Institutional Review Board/ Privacy Board (approval number: 2012-0795), and all patients provided written informed consent for the genetic analysis.
Targeted Sequencing
All tumor specimens were reviewed by pathologists to determine the percentage of viable tumor and its adequacy for sequencing. DNA extraction, library construction, and high-throughput sequencing were performed using CancerSCAN panel version 1 containing 83 genes or version 2 containing 375 genes, as previously described. 13 For cohort 1, seven and 68 patients are tested on version 1 and 2, respectively. For cohort 2, three and 79 patients are tested on version 1 and 2, respectively. Variant detection, annotation, and filtering were performed using a previously described pipeline. 14 To avoid false-positive results caused by insignificant germline variants and multiple comparisons, only variants predicted to have functional impact were selected. The included variants were protein-truncating mutations predicted by ANNOVAR, actionable variants described in OncoKB, single-nucleotide variants/indels detected more than once in The Cancer Genome Atlas data, and TP53-disruptive mutations, as defined by Poeta et al. [15] [16] [17] [18] The cutoff for tumor mutational burden of at least 9 mutations per megabase and we divided into two groups; low (1-9 mutations/mb) and high (9 mutations/mb or greater). 19 
Statistical Analysis
Progression-free survival (PFS) and overall survival (OS) were measured from the first day of treatment with EGFR-TKI to tumor progression and death, respectively. Patients were censored on February, 28, 2018, if alive and progression-free. Patients without a known date of progression were censored at the time of the last followup. Genetic alterations with frequency greater than 2 were included in the analysis. The Kaplan-Meier method was used to estimate PFS and OS, and differences according to the co-occurring genetic alteration were compared using the log-rank test. Multivariate survival analysis was performed using the Cox proportional hazards model. Factors included in multivariate analysis were selected based on four criteria: (1) basic demographic characteristics; (2) well-known EGFR-TKI response predictive factors; (3) previously reported prognostic factor; and (4) genetic alterations which were statistically significant in univariate analysis. All p values were based on a two-tailed hypothesis, and statistical significance was defined as p < 0.05.
Results
Patient Characteristics
Between January 2014 and May 2017, 307 NSCLC patients received targeted NGS testing on tumor samples. Among these patients, 75 for whom NGS data had been obtained before treatment with EGFR-TKI 1st/2nd were included in cohort 1. Of the 177 patients who underwent tumor re-biopsy and received NGS testing after EGFR-TKI 1st/2nd failure, 112 (63.3%) harbored a T790M mutation. Eighty-two patients who developed a T790M-related resistance mutation and were subsequently treated with EGFR-TKI 3rd were included in cohort 2. The clinical characteristics for these patients are shown in Table 1 . The median follow-up time was 30.9 months (range, 1.4-52.6 months) and 23.9 months (range, .8-37.1 months) in cohorts 1 and 2, respectively. In cohort 1, the mean age was 58.5 (SD, 11.0) years; 51 patients (68.0%) were female, 48 patients (64.0%) had never smoked, and 37 patients (49.3%) harbored an EGFR exon 19 deletion. In cohort 2, the mean age was 57.3 (SD, 9.1) years, 55 patients (67.1%) were female, 48 patients (58.5%) had never smoked, and 54 patients (65.9%) had an EGFR exon 19 deletion.
Genomic Predictors of Survival Outcome for First-or Second-Generation TKI Therapy
We performed survival analysis based on mutation profiles in cohort 1. The mutational heatmap provides an overview of genomic alterations that were found in at least three tumor samples (Fig. 1A) . We describe the frequency of each mutation and the result of survival analysis according to the mutation in Supplementary  Table 1 . The most frequent co-occurring alterations in cohort 1 were TP53 (n ¼ 43, 57.3%), CTNNB1 (n ¼ 7, 9.3%), PIK3CA (n ¼ 6, 8.0%), and RB1 (n ¼ 5, 6.7%). The TP53 mutation was associated with a trend toward a shorter PFS as compared with wild-type TP53 (median PFS, 12.5 [95% confidence interval (CI): 11. Fig. 3 ).
Genomic Predictors of Survival Outcome for Third-Generation TKI Therapy
In cohort 2, tumor samples obtained after failure of EGFR-TKI 1st/2nd treatment were used for molecular profiling (Fig. 1B) . The frequency of concurrent mutations and survival analysis according to the mutations are presented in Supplementary Table 2 . The most frequent co-occurring alterations were TP53 (n ¼ 50, 60.9%), CTNNB1 (n ¼ 10, 12.3%), RB1 (n ¼ 7, 8.6%), and PIK3CA (n ¼ 6, 7.4%), with the most frequent concurrent amplifications found in MDM2 (n ¼ 8, 9.9%). TP53 mutation had a significantly shorter PFS and worse OS as compared with wild-type TP53 (median PFS, 8 (Fig. 3D ).
Pathway Alterations in Cohort 2
We then performed pathway-level analysis, including for the TP53 pathway, cell cycle pathway, PI3K pathway, and Wnt pathway in cohort 2. Genes included in each pathway are described in Supplementary Supplementary Fig. 4 ). 
Multivariate Survival Analyses of Prognostic Factors in Cohort 2
We evaluated patients in cohort 2 for correlations between PFS1 (PFS to first-line EGFR-TKI 1st/2nd ) and PFS2 (PFS to second-line EGFR-TKI 3rd ). According to the duration of PFS, we divided cohort 2 into two groups: short PFS1 (median PFS 12 months or less; n ¼ 61) and long PFS1 (median PFS greater than 12 months; n ¼ 21). Comparison of PFS2 with these two groups revealed that long PFS1 led to longer PFS2 (7.8 Fig. 5 ).
We then conducted multivariate analysis using potential predictors of survival outcome, including PFS1, age, sex, smoking status, ECOG score, EGFR subtype, and presence of the aforementioned alterations. We found that only TP53 (Fig. 2B) . Regarding OS, male, ECOG greater than 1, TP53, RB1, and MDM2 alterations were associated with shorter OS (Supplementary Fig. 6 ).
Longitudinal Genomic Profiling
To illustrate the importance of NGS testing in patient care, we performed longitudinal genomic analysis of a patient with NGS data from serially acquired tissues. The patient was initially diagnosed as having adenocarcinoma with an EGFR L858R mutation and received erlotinib for 13 months until the progression of pleural seeding was noted on computed tomography scan (Fig. 4) . EGFR T790M was subsequently detected in pleural tumors, and second-line therapy with osimertinib was initiated. After 16 months of treatment with osimertinib, computed tomography scan revealed an increased size of the primary lung tumor and pleural seeding, and histologic examination of the progressed lung tumor showed small-cell transformation along with the disappearance of the T790M mutation according to genetic testing. After 4 cycles of chemotherapy, the patient presented neurologic symptoms, with brain magnetic resonance imaging revealing a new metastatic lesion that retained adenocarcinoma morphology and the T790M mutation. We analyzed clonal evolution of this tumor using NGS testing performed on preosimertinib pleural tumor tissue, post-osimertinib lung tumor tissue, and metastatic brain tumor tissue. Subclones harboring EGFR T790M and FANCA R1400H disappeared in post-osimertinib lung tumor tissue, but metastasized to the brain. Additionally, a newly emerged subclone in post-osimertinib lung tumor tissue harbored mutations in TP53, NOTCH1, NCOR1, and PHLPP2 possibly associated with small-cell transformation. On the other hand, a newly emerged subclone in metastasized brain tumor tissue harbored mutations in FAT3, EPHB1, and the chromatin modifiers CHD2, TRRAP, SMARCD1, and DNMT3A, which might be associated with brain metastasis.
Discussion
Our study represents a comprehensive analysis of cooccurring genomic alterations to assess their predictive efficacy of the clinical benefits of EGFR-TKI treatment in NSCLC. In this study, we showed that (1) a co-occurring TP53 mutation was a poor prognostic factor for patients treated with EGFR-TKI 1st/2nd ; (2) TP53 mutation, RB1 mutation, PTEN mutation, and MDM2 amplification were poor prognostic factors for EGFR-TKI 3rd ; and (3) genomic studies using NGS of sequential and multisite biopsy samples pre-and post-treatment improved our understanding of the mutational process of complex clonal evolution and tumor heterogeneity. These data suggest that the observed clinical heterogeneity in patients with EGFR-mutant NSCLC is likely due in part to differences in co-occurring molecular events. These molecular biomarkers can be used to predict outcomes in EGFR-mutant NSCLC patients for EGFR-targeted therapy.
A recent study showed that co-occurrence of TP53 mutation with an EGFR mutation was significantly associated with shorter PFS and OS in EGFR-TKI 1st/2nd pretreated samples. 11, 12 We also observed TP53 mutation as an independent, poor prognostic factor in patients treated with EGFR-TKI 3rd in addition to EGFR-TKI 1st/2nd . Notably, multivariate analysis showed that TP53, RB1, PTEN, and MDM2 alterations were significant prognostic factors in patients receiving EGFR-TKI 3rd therapy. This observation supports the concept that it is not just major driver mutations that affect therapeutic response and clinical outcomes and highlights the importance of conducting comprehensive genome sequencing in patients harboring an EGFR mutation. When an EGFR-TKI blocks EGFR signaling, additional key genetic events, such as RB1 inactivation, occur and facilitate cell differentiation into a lineage that does not require EGFR signaling. 20 RB1 is an important regulator of cell cycle progression, and its loss is involved in the small-cell transformation of NSCLC. 21 No small-cell component was identified by histologic review of tissue slides of RB1 mutated tumors in our two cohorts; however, RB1 mutation is reportedly associated with poor prognosis, which is consistent with our results. 22 Although our study cohort is not longitudinal analysis with paired pre/post EGFR TKI treatment tumor samples, four patients were included in both cohort 1 and cohort 2. In these patients, two acquired PTEN mutations (stop gain mutation in PTEN p.E157* and splice site deletion in PTEN c.729-4302_739 del) were identified after treatment with first-/second-generation EGFR-TKI and were associated with worse PFS in cohort 2. PTEN acts as a tumor suppressor by inhibiting PI3K pathway activation. Given that the PI3K pathway is downstream of the EGFR-signaling pathway, it is likely that PTEN inactivation plays an important role in progression and/or therapeutic resistance in patients treated with EGFR-TKIs. 23 A previous report showed that high expression of PTEN increases survival in patients with and EGFR-activating mutation. 24 Consistent with previous studies, we showed that a PTEN-inactivating mutation and PI3K-pathway alteration are associated with shorter PFS; however, PIK3CA mutation did not show a significantly different PFS associated with treatment with EGFR-TKI 3rd . 25 Recent studies also suggested the functional importance of co-occurring genetic alterations in advanced EGFR-mutant lung cancers. 8, 9, 26 Blakely et al. 9 monitored co-occurring genetic alterations in the plasma of patients and identified a potential role for WNT/b-catenin and cell-cycle-gene alterations (CDK4 and CDK6). Although these new data provide insights concerning how cooccurring genetic alterations cooperate with a primary driver mutation to influence tumor progression, the question of what kinds of co-occurring genetic alterations relate to the marked diversity of individual patient outcomes remains open. Recently, cell-free DNA analysis has shown significant clinical utility and high concordance with tissue-based genomic testing. [27] [28] [29] However, these noninvasive liquid biopsies cannot identify the full spectrum of mutations possibly affecting clinical outcomes due to the limited number of genes analyzed (typically 68 to 70 genes) or other concomitant resistant mechanisms. 9, 27, 30 Furthermore, cell-free DNA analysis might miss actionable mutations, which could be a result of small tumor volume or intratumor heterogeneity resulting in very low frequencies. 27, 28, 31 Therefore, comprehensive analysis of genomic alterations in tumor tissues via high-throughput panel sequencing can be advantageous to understand the genetic mechanisms associated with tumor progression and therapeutic resistance.
PFS2 is more affected by concurrent genetic alterations than PFS1. We speculate that additional genetic alterations promoting the bypass of EGFR blockade might occur after EGFR-TKI treatment. Co-existence of genetic alterations resulting in insufficient target suppression, as well as tumor heterogeneity, might play a role in acquisition of resistance to EGFR-TKI therapy. This suggests that novel clinical-trial designs will be needed to generate alternative treatment strategies, such as combination strategies targeting more than one potentially actionable alteration in EGFR-mutant NSCLC.
Limitations
Our study has limitations: (1) the use of a retrospective database limited our ability to investigate other sources of potential bias; (2) we used a single center of accrual; (3) NGS data on patients who received upfront third-generation TKI were excluded from this study; (4) patients treated with different EGFR-TKI of different clinical efficacy are included; and (5) the generalizability of our study findings must be considered.
Conclusions
In conclusion, our results highlight that EGFRmutated tumors have significant inter-and intratumor heterogeneity along with various co-occurring mutations that determine the clinical efficacy of TKIs in EGFRmutated NSCLC patients. Our analysis shows that NGS enabled identification of not only potentially actionable mutations, but also important co-occurring genomic alterations that have impact on prognosis of EGFR-TKI treatment. Prospective identification of patients with these concurrent genomic alterations should be considered in clinical trials.
